Aug 2, 2026
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee determined that efficacy data from Replimune's Ignyte study for RP1 is evaluable and clinically meaningful, voting 10 to 3 in favor.
Researchers have developed engineered probiotic bacteria designed to overcome the 'cold' tumor microenvironment in pancreatic cancer, potentially enhancing the effectiveness of immunotherapy treatments for this difficult-to-treat disease.
New research analyzing patients from Kite Pharma's Yescarta clinical trials has identified inherited genetic signatures that can predict which patients are at higher risk for toxic side effects from CAR-T cell therapy, potentially enabling better patient selection and monitoring for this cancer immunotherapy.
Researchers report safety and preliminary efficacy results from a phase Ib clinical trial testing personalized neoantigen-pulsed autologous dendritic cell vaccination in patients with newly diagnosed glioblastoma, a deadly brain cancer with limited treatment options.
China's National Medical Products Administration has approved satricabtagene autoleucel (Satri-cel, CT041, Kaileimei®), marking the first CAR-T cell therapy approved globally for treating solid tumors, specifically for CLDN18.2-positive, HER2-negative advanced gastric and gastroesophageal junction adenocarcinoma.
New clinical trial results presented at the American Society of Clinical Oncology show that Moderna's experimental personalized mRNA vaccine, combined with immunotherapy, significantly reduced the risk of deadly melanoma returning after five years. The vaccine is custom-made for each patient based on their specific tumor.
Clinical trial results demonstrate that immunotherapy as first-line treatment provides clinical benefit for patients with advanced colorectal cancer, offering an alternative to chemotherapy for a disease increasingly affecting younger patients.
Scientists discovered that mRNA cancer vaccines can still destroy tumors even when a key immune cell type is missing, revealing unexpected mechanisms of action. The research advances understanding of how Nobel Prize-winning mRNA technology can be adapted from COVID-19 vaccines to fight cancer.